Your browser doesn't support javascript.
loading
A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia.
Elalfy, Mohsen; Reda, Marwa; Elghamry, Islam; Elalfy, Omar; Meabed, Mohamed; El-Ekiaby, Nada; El-Hawy, Mahmoud A; Goubran, Hadi; El-Ekiaby, Magdy.
Afiliação
  • Elalfy M; Department of Pediatric Hematology, Ain Shams University Hospitals, National Research Center, Cairo, Egypt.
  • Reda M; Department of Pediatric Hematology, Ain Shams University Hospitals, National Research Center, Cairo, Egypt.
  • Elghamry I; Department of Pediatric Hematology, Ain Shams University Hospitals, National Research Center, Cairo, Egypt.
  • Elalfy O; Complementary Medicine Department, National Research Center, Cairo, Egypt.
  • Meabed M; Department of Pediatrics, Beni-Suef University, Beni-Suef, Egypt.
  • El-Ekiaby N; School of Medicine, Health Sciences Research Department, New Giza University, Giza, Egypt.
  • El-Hawy MA; Department of Pediatrics, Menoufia University, Menoufia, Egypt.
  • Goubran H; University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • El-Ekiaby M; Hematology Unit, Blood Transfusion Center, Shabrawishi Hospital, Giza, Egypt.
Transfusion ; 57(12): 3019-3025, 2017 12.
Article em En | MEDLINE | ID: mdl-28880361
ABSTRACT

BACKGROUND:

Because there is a global shortage of intravenous immunoglobulin, there is a need for new products to fill the gap. STUDY DESIGN AND

METHODS:

This was a multicenter, open-label study investigating the safety and efficacy of a newly developed mini-pool intravenous immunoglobulin G for children with immune thrombocytopenia. Seventy-two patients ages 1 to 18 years with newly diagnosed (<1 month) immune thrombocytopenia who had platelet counts from 5 to 20 × 109 /L with no serious bleeding were recruited from four centers in Egypt. Eligible patients were randomized into three groups 111. Group A (n = 24) received blood group-specific mini-pool intravenous immunoglobulin in a dose equivalent to immunoglobulin 1 g/kg over 6 to 8 hours, Group B (n = 24) received standard intravenous immunoglobulin (approximately 1g/kg) as a single dose, and Group C (n = 24) did not receive any platelet-enhancing therapy. Parents signed informed consent.

RESULTS:

Of the patients who received mini-pool intravenous immunoglobulin, 14 achieved a complete response (CR) (58.8%), and four had a response (16.6%). Of the patients who received intravenous immunoglobulin G, 16 achieved a complete response (66.6%), and four had a response (16.6%). In Group C, eight patients achieved a complete response (33.3%), and four had a response (16.6%). The median time to response was 8, 9, and 21 days in Group A, B, and C, respectively, which was significantly higher in Group C than Groups A and B (p < 0.001). Patients in Groups A and B reported 16 adverse drug reactions.

CONCLUSION:

Mini-pool intravenous immunoglobulin G was well tolerated, presented no safety issues, and was effective in the treatment of immune thrombocytopenia, with efficacy comparable to that of the standard intravenous immunoglobulin G group, and it was significantly more effective than no treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática / Imunoglobulinas Intravenosas Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male País/Região como assunto: Africa Idioma: En Revista: Transfusion Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Egito

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática / Imunoglobulinas Intravenosas Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male País/Região como assunto: Africa Idioma: En Revista: Transfusion Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Egito